



15 Earhart Drive, Suite 101, Amherst, NY 14221

BOTULINUM TOXIN AUTHORIZATION AND REAUTHORIZATION

TEL: (716) 929-1000 | 1-800-809-4763 FAX: (716) 532-7360

Member Name:			Today's Date:			Date Needed:				
Date of birth:		Sex:	Weight:		Prescriber:			Hospital/Clinic:		
Home Phone Number: () ()			Phone Number: () ()			Fax Number: () ()				
Home Address:		City:	State:	Zip:		Address:		City:	State:	Zip:
Payor: <input type="checkbox"/> Independent Health <input type="checkbox"/> Anne Arundel Health System <input type="checkbox"/> Pharmacy Benefit Dimensions			<input type="checkbox"/> Commercial <input type="checkbox"/> Medicaid		<input type="checkbox"/> Medicare <input type="checkbox"/> Self-funded		Prescriber specialty:			
Insurance ID:			Group Number:			Allergies:				

STATEMENT OF MEDICAL NECESSITY	DRUG SELECTION
<p>Primary Diagnosis: _____</p> <p>ICD10 Code _____</p> <p>OTHER DIAGNOSIS/ICD10 CODE: _____</p> <p>- Has Functional Impairment been demonstrated with this condition? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>- Please submit office visit notes to support this diagnosis</p> <p>FOR ALL DIAGNOSES: Please state all medications tried and failed for this condition, as well as response to treatment: _____</p> <p>_____</p> <p>_____</p> <p>FOR CHRONIC MIGRAINE:</p> <p>Please submit headache diary, with record of headache frequency and analgesic usage for the three prior months, or office notes detailing the frequency and severity of patient's headaches:</p> <p>- Will patient be using botulinum toxin in combination with a CGRP receptor antagonist? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>IF YES:</p> <p>- Has patient had a reduction in overall migraine days or reduction in number of severe migraine days per month with CGRP use? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>- Does Patient continue to experience a significant number of migraine headache days or severe migraine days per month requiring additional therapy for migraine prevention? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>FOR CHRONIC MIGRAINE REAUTHORIZATION:</p> <p>- Please submit updated Headache Diary or Office Notes documenting at least 50% improvement from baseline</p> <p>- Is the patient using concurrently with a CGRP Receptor antagonist? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>IF YES:</p> <p>- Has the patient had further reduction in the overall number of migraine days or reduction in number of severe migraine days per month compared to monotherapy with the initial agent? <input type="checkbox"/> Yes <input type="checkbox"/> No</p>	<p><input type="checkbox"/> New Authorization <input type="checkbox"/> Reauthorization*</p> <p><input type="checkbox"/> Botox <input type="checkbox"/> Dysport</p> <p><input type="checkbox"/> Myobloc</p> <p>Dose: _____ Frequency: _____</p> <p>Estimated Start of Therapy: _____</p> <p>FOR DYSPORT AND MYOBLOC ONLY:</p> <p>- Has the patient tried and failed, or have a contraindication to both Botox and Xeomin? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>PRIMARY AXILLARY HYPERHIDROSIS:</p> <p>- Is inadequately managed with topical agents where the excessive sweating results in a functional deficit? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>- Has the patient tried and failed a reasonable trial of aluminum chloride 20% topical solution? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>OAB WITH URINARY INCONTINENCE</p> <p>- Has the patient had an inadequate response or intolerance to an anticholinergic medication? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>URINARY INCONTINENCE DUE TO DETRUSOR ACTIVITY DUE TO A NEUROLOGIC CONDITION</p> <p>- Has the patient had an inadequate response or intolerance to an anticholinergic medication? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>FOR REAUTHORIZATION:</p> <p>- Has the patient had a positive response to treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>- Please Submit updated office notes documenting response and treatment plan</p>